Alkem Laboratories is currently trading at Rs. 3369.05, up by 8.05 points or 0.24% from its previous closing of Rs. 3361.00 on the BSE.
The scrip opened at Rs. 3346.55 and has touched a high and low of Rs. 3373.65 and Rs. 3346.55 respectively. So far 42 shares were traded on the counter.
The BSE group 'A' stock of face value Rs. 2 has touched a 52 week high of Rs. 3624.80 on 09-May-2023 and a 52 week low of Rs. 2835.05 on 02-Mar-2023.
Last one week high and low of the scrip stood at Rs. 3400.00 and Rs. 3282.65 respectively. The current market cap of the company is Rs. 40185.80 crore.
The promoters holding in the company stood at 57.16%, while Institutions and Non-Institutions held 21.13% and 21.70% respectively.
Alkem Laboratories has launched Cetuxa, the world's first biosimilar of Cetuximab, used for the treatment of head and neck cancer. The introduction of the medication is in line with the company's endeavour to ensure affordability, accessibility and availability while saving the lives of critically ill cancer patients.
Cetuxa is administered as an intravenous infusion and is available as 100 mg (2 mg/mL) in a single-dose vial. In India, more than 76,000 patients are eligible for the use of cetuximab for the management of head and neck cancer. Currently, only around 1,611 patients are managed by this therapy. Its reach in India is limited partly due to its high cost. To address this issue, it has launched an affordable biosimilar, which is backed by indigenous research and production.
Alkem Laboratories is a leading Indian pharmaceutical company with global operations, engaged in the development, manufacture and sale of pharmaceutical and nutraceutical products. The company produces branded generics, generic drugs, active pharmaceutical Ingredients (APIs) and nutraceuticals, which it markets in India and International markets.
| Company Name | CMP |
|---|---|
| Sun Pharma Inds. | 1818.30 |
| Dr. Reddys Lab | 1332.35 |
| Cipla | 1473.25 |
| Lupin | 2161.30 |
| Zydus Lifesciences | 973.40 |
| View more.. | |
MoneyWorks4Me rating and ranking of funds for SIP is available to subscribers only. Moneyworks4Me is not a rating and ranking agency, however it is required that users have a way of selecting funds and building a Portfolio. The method used by it are described below to enable users to understand the logic behind the rating and ranking Subscriber will find more details on this in the various content made available from time to time. In case you need more please write to besafe@moneyworks4Me.com
MoneyWorks4Me rates and ranks mutual funds based on the following data-driven system:
Funds ranking in screeners: Performance Consistency and Quality are two parameters used for ranking funds for SIP. The ranking as follows GG, GO, GR, OG, OO, OR, RG, RO and RR.
With the same color-coded funds, the one with the higher Average 3-year rolling returns (over 5 to 10 years), the number that appears in the Performance tag, ranks higher.
Here is the summary:
The third tag Upside Potential is not relevant for SIP. It is relevant for lumpsum investments in Mutual Funds.
Make an informed decision for Stocks
Invest using an intelligent system with powerful data-driven tools that help you identify opportunities and make informed buy-hold-sell decisions
Buy quality Stocks when they are available at reasonable prices and supported by an upward price trend and Sell when they are Overvalued using the Decizen Rating System. Covers 3500+ stocks
Limited to the first 10 users today!
Practical Stock Investing Hand Book
By - Raymond Moses
Founder of MoneyWorks4Me | Consultant | Trainer | Author | TEDx Speaker
Register & Get Instant Access!Don't miss out! First 10 users today get it FREE
With this 4 hrs Masterclass, you’ll be able to:
Download APP
